Which account would you like to be logged in as?

Forgot Password?

Sign Up!

Visa/MasterCard and Discover Users
Flip your credit card over and look at the signature box. You should see either the entire 16-digit credit card number or just the last four digits followed by a special 3-digit code. The 3-digit code is your Card Security Code.

American Express Credit Card Users
Look for the 4-digit code printed on the front of your card just above and to the right of your main credit card number. The 4-digit code is your card Identification Number (CID).

What is a discount code?
Generic discount code text needs to go here

Newsletter
jun 9
2011
Release date

Advancing Myeloma Treatment Paradigms: Key Findings from the 13th International Myeloma Workshop

Multiple Myeloma

MEDIA: Newsletter

Estimated time to complete activity: 1.0 hour | Release date: Thursday, June 09, 2011 | Expiration date: Friday, June 08, 2012

INTRODUCTION

The 13th International Myeloma Workshop was recently held, May 3-6, 2011, in Paris, France. This newsletter provides a comprehensive review of key experimental and clinical data presented at the conference as well as further highlights scientific advancement, knowledge, and insight gained from this international scientific symposium.

FEATURED CONTENT

Newly Diagnosed Multiple Myeloma
Consolidation and Maintenance
New Therapeutics
Diagnostic and Prognostic
Supportive Care

EDITORS


Rafat Abonour, MD

Professor of Medicine
Pathology and Laboratory Medicine
Dean, Clinical Research
Indiana University
Medical Director, Multiple Myeloma Program
Indiana University Medical Center
Indianapolis, Indiana

Sagar Lonial, MD

Professor
Vice Chair of Clinical Affairs
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

TARGET AUDIENCE

The intended audience for this activity is community-based hematologists, hematologist-oncologists, medical oncologists, and oncology specialty pharmacists caring for patients with multiple myeloma.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to:

  • Recognize biologic pathways of significance in myeloma pathogenesis and resistance and their implications on treatment selection and response
  • Describe the potential role of novel treatment approaches in the management of patients with newly diagnosed myeloma
  • Compare treatment options available for the treatment of patients with relapsed/refractory myeloma with respect to efficacy and toxicity parameters
  • Discuss advances in mobilization and stem cell transplant preparative regimens in myeloma

PHYSICIAN CONTINUING EDUCATION

Accreditation Statement
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Educational Concepts Group, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION

ACPE Logo Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

Educational Concepts Group, LLC designates this continuing education activity for 1.0 contact hour (0.10 CEU) (UAN 0199-0000-11-017-H01-P).

Type of activity: Knowledge-based

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CE credit for this activity. During the period Thursday, June 09, 2011 through Friday, June 08, 2012, participants must 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.

CME/CE CREDIT

Physicians and pharmacists who complete the post-activity assessment with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.

POLICY ON DISCLOSURE

It is the policy of ECG that the faculty, authors, planners, and other persons who may influence content of this CME/CE activity disclose all relevant financial relationships with commercial interests in order to allow ECG to identify and resolve any potential conflicts of interest.

The Following Faculty Members Have Declared Relevant Financial Relationships

Rafat Abonour, MD Grants/Research Support Celgene Corporation
Millennium Pharmaceuticals, Inc.
Consultant Fees Celgene Corporation
Millennium Pharmaceuticals, Inc.
Honorarium Celgene Corporation
Millennium Pharmaceuticals, Inc.
Speakers' Bureau Celgene Corporation
Millennium Pharmaceuticals, Inc.
Sagar Lonial, MD Consultant Fees Bristol-Myers Squibb
Celgene Corporation
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Novartis
Onyx Pharmaceuticals, Inc.

Staff Disclosure
Planners and managers at ECG have no relevant financial relationships to disclose.

ACKNOWLEDGEMENT

The editors wish to thank Sara R. Fagerlie, PhD, for assistance in writing this document.

DISCLOSURE OF OFF-LABEL USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT

This activity is supported by educational grants from the following: Celgene Corporation, Merck & Co., Inc., Onyx Pharmaceuticals, Inc.

CME/CE INQUIRIES

For further information, please contact:
Educational Concepts Group, LLC
1300 Parkwood Circle SE, Suite 325
Atlanta, Georgia 30339
Phone: 1.866.933.1681
Fax: 1.866.933.1692
www.educationalconcepts.net

None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.

Yes, I have read the information above and am interested in participating.

More Online Activities